Company Overview
| Stock Name | 亞盛醫藥集團 - B |
|---|---|
| Stock Code | 06855 |
| Company Full Name | 亞盛醫藥集團 - B |
| Industry | 醫療保健 |
| Principal Activities | 主要從事生物制藥業務，核心治療領域包括癌癥、ＨＢＶ及衰老相關疾病。 |
| Listing Date | 2019-10-28 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國江蘇省蘇州市蘇州工業園區星湖街218號B7樓7層 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | http://www.ascentagepharma.com |
| Share Registrar | |
| Registrar Contact | (852)2980 1333 |
| A-Share/US Dual Listing | No data |
Offering Information
| Offering Mechanism | To be extracted |
|---|---|
| Offer Price | HK$ 34.20 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | To be extracted |
| Global Offering Shares | To be extracted |
| HK Public Offer Shares (Initial) | To be extracted |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | To be extracted |
| Offer Ratio | To be extracted |
| Total Shares Post-IPO | To be extracted |
| Greenshoe (Over-allotment Option) | To be confirmed |
| Stabilizing Manager (Greenshoe) | — |
| Cornerstone Share | 37.6% |
| Clawback Tiers | To be extracted |
| Reallocation Option | To be confirmed |
| Total Global Offering Size | HK$ 208,295,100 |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | To be extracted |
| P/E Ratio | To be extracted |
| Profit/Loss Status | To be extracted |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
First Day Performance
| First Day Close | HK$ 37.6 |
|---|---|
| First Day Open | HK$ 53.0 |
| First Day Change | 9.94% |
| First Day Volume | 13246000.0 |
| First Day Turnover | 594180000.0 |
Use of Proceeds
| Use of Proceeds | 1、所得款項凈額約42%（約130.9百萬港元）分配到研發，將核心產品HQP1351商業化 2、所得款項凈額約13%（約40.5百萬港元）用于APG-1252持續及規劃臨床試驗； 3、所得款項凈額約19%（約59.2百萬港元）用于APG-2575持續及規劃臨床試驗； 4、所得款項凈額約19%（約59.2百萬港元）用于APG-115持續及規劃臨床試驗； 5、所得款項凈額約6%（約18.7百萬港元）分配到APG-1387及APG-2449其余臨床計劃的持續及規劃臨床試驗； 6、所得款項凈額約1%（約3.1百萬港元）分配到我們的營運資金及一般公司用途。 |
|---|
Underwriting Syndicate
Joint Sponsors (2)
Merrill Lynch (Asia Pacific) Limited CE AAC198
花旗环球金融亚洲有限公司 CE AAA137
Overall Coordinators (3)
Merrill Lynch (Asia Pacific) Limited CE AAC198
花旗环球金融亚洲有限公司 CE AAA137
华泰金融控股（香港）有限公司 CE AOK809
Joint Bookrunners (7)
Merrill Lynch (Asia Pacific) Limited CE AAC198
花旗环球金融亚洲有限公司 CE AAA137
华泰金融控股（香港）有限公司 CE AOK809
建银国际金融有限公司 CE AJO225
华兴证券（香港）有限公司 CE AZX839
招银国际金融有限公司 CE AJB801
海通国际证券有限公司 CE AAF806
Joint Lead Managers (7)
Merrill Lynch (Asia Pacific) Limited CE AAC198
花旗环球金融亚洲有限公司 CE AAA137
华泰金融控股（香港）有限公司 CE AOK809
建银国际金融有限公司 CE AJO225
华兴证券（香港）有限公司 CE AZX839
招银国际金融有限公司 CE AJB801
海通国际证券有限公司 CE AAF806
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | 中国生物制药有限公司 | 156,854,880 HKD | — | 37.65% | — | 6 months | 2020-04-28 |
Directors & Management
| Chairman | 楊大俊 |
|---|---|
| Company Secretary | 梁凱恩 |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 楊大俊及關連人士(24.37%);先進制造產業投資基金(有限合伙)(6.71%);田源(6.45%) |
|---|
